Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Oct 11 · below the Ichimoku cloud · RSI 36 · MACD below its signal
None of the 29 investors followed here reported a position in 2616.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 2616.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Oct 5, 2026 | Li (Wei)Chairman of the Board | — | 20.8K | — |
| Oct 5, 2026 | Yang (Jianxin)Chief Executive Officer | — | 63K | — |
| Oct 5, 2026 | Hu (Edward)Director (Non-Executive) | — | 20.8K | — |
| Sep 29, 2026 | Yang (Jianxin)Chief Executive Officer | — | 6.9K | — |
| Sep 21, 2026 | Yang (Jianxin)Chief Executive Officer | Acquisition at price 0.72 per share. | 291.5K | $209.38K |
| Sep 17, 2026 | Yang (Jianxin)Chief Executive Officer | Acquisition at price 0.69 per share. | 72K | $49.79K |
| Sep 16, 2026 | Yang (Jianxin)Chief Executive Officer | Acquisition at price 0.67 per share. | 132.5K | $88.42K |
| Sep 3, 2026 | Li (Wei)Chairman of the Board | — | 41.7K | — |
| Sep 3, 2026 | Yang (Jianxin)Chief Executive Officer | — | 208.5K | — |
| Sep 3, 2026 | Hu (Edward)Director (Non-Executive) | — | 41.7K | — |
| Jul 5, 2026 | Hu (Edward)Director (Non-Executive) | — | 20.8K | — |
| Jul 5, 2026 | Li (Wei)Chairman of the Board | — | 20.8K | — |
| Jul 5, 2026 | Yang (Jianxin)Chief Executive Officer | — | 63K | — |
| Jun 29, 2026 | Li (Wei)Chairman of the Board | — | 62.5K | — |
| Jun 29, 2026 | Yang (Jianxin)Chief Executive Officer | — | 448.9K | — |
| Jun 29, 2026 | Yang (Jianxin)Chief Executive Officer | Acquisition at price 0.59 per share. | 331K | $195.92K |
| Jun 29, 2026 | Hu (Edward)Director (Non-Executive) | — | 62.5K | — |
| Jun 22, 2026 | Yang (Jianxin)Chief Executive Officer | — | 56.5K | — |
| Jun 11, 2026 | Li (Wei)Chairman of the Board | Acquisition at price 0.58 per share. | 100K | $58.20K |
| Jun 11, 2026 | Yang (Jianxin)Chief Executive Officer | Acquisition at price 0.58 per share. | 200K | $116.64K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 0.9 | 24.4 | 30.2 | 6.9 | -13.4 | -41.5 | -8.3 | 33.1 | 2.6 | -19.0 | −10.2% | ||
| 2025 | 1.7 | 46.6 | -3.5 | -14.8 | 40.4 | 7.8 | 69.1 | 49.0 | -29.4 | -17.6 | -2.4 | -12.9 | +131.3% |
| 2024 | -28.2 | -1.8 | -41.3 | -6.4 | 31.8 | -1.7 | 8.8 | 25.0 | 25.8 | 10.3 | -0.5 | 7.5 | +1.3% |
| 2023 | 7.3 | -20.9 | -9.7 | -6.5 | -14.5 | -12.3 | 1.6 | -11.9 | -17.0 | 13.5 | 9.5 | -1.3 | −51.0% |
| 2022 | -27.1 | 7.1 | -22.0 | 0.0 | 0.0 | 4.2 | -21.0 | 16.1 | -27.4 | -3.4 | 2.4 | 33.8 | −44.0% |
| 2021 | 3.6 | -4.0 | -7.9 | 20.2 | 20.3 | 27.8 | -16.0 | -8.9 | -17.6 | -10.4 | 7.7 | -20.5 | −18.1% |
| 2020 | 5.0 | -3.0 | -17.1 | -7.9 | -1.5 | 40.2 | -6.0 | -11.2 | 6.5 | 15.7 | -16.3 | 6.0 | −1.9% |
| 2019 | 28.1 | -13.5 | -16.3 | 0.2 | 4.2 | -4.0 | 9.4 | -16.5 | 6.8 | -8.4 | −16.9% |
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junction adenocarcinoma, esophageal squamous cell carcinoma, and relapsed or refractory natural killer/T cell lymphoma; GAVRETO (pralsetinib), a RET inhibitor to treat patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers, as well as NSCLC and multiple tumors; and AYVAKIT (avapritinib), a KIT/PDGFRA inhibitor, has been approved by the China NMPA for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. It has strategic partnerships with Pfizer, Sanofi, Hengrui, 3SBio Inc., Allist, Ewopharma, Pharmalink, SteinCares, and Gentili. CStone Pharmaceuticals was incorporated in 2015 and is headquartered in Suzhou, China.
Buy / hold / sell counts
No recent headlines.